Destination therapy

Heart Pump Device Market by Product, Type, Therapy and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 9, 2021
Medical devices, Health, Cardiology, Interventional cardiology, Medical specialties, Medicine, Medical devices, Clinical medicine, Prosthetics, Ventricular assist device, Artificial heart, Destination therapy, Thoratec, Abiomed

The global heart pump device market is projected to reach USD 5.5 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 21.6% from 2021 to 2026.

Key Points: 
  • The global heart pump device market is projected to reach USD 5.5 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 21.6% from 2021 to 2026.
  • Ventricular assist devices are expected to hold the largest share of the heart pump device market, by product in 2021
    Based on products, the heart pump devices market is segmented into ventricular assist devices, intra- aortic balloon pumps, and total artificial hearts.
  • Implantable heart pump devices are expected to hold the largest share of the heart pump device market, by type in 2021
    Based on type, the market is segmented into implantable heart pump devices and extracorporeal heart pump devices.
  • Bridge-to-transplant is expected to hold the largest share of the heart pump device market, by therapy in 2021
    Based on therapy, the market is segmented into bridge-to-transplant (BTT), bridge-to-candidacy (BTC), destination therapy (DT), and other therapies.

FineHeart Achieves Milestone for Its Miniaturized Heart Pump Technology With Successful Completion of 30-day Preclinical Study

Retrieved on: 
Tuesday, October 20, 2020
Biotechnology, Medical devices, Health, Clinical trials, Cardiology, Interventional cardiology, Cardiology, Medical devices, Medicine, Prosthetics, Destination therapy, Ventricular assist device

FineHeart, SA, a preclinical-stage medical device company developing an Implantable Cardiac Output Management System (ICOMS) to address the unmet need of patients suffering from severe heart failure, today announced the successful completion of a 30-day preclinical study.

Key Points: 
  • FineHeart, SA, a preclinical-stage medical device company developing an Implantable Cardiac Output Management System (ICOMS) to address the unmet need of patients suffering from severe heart failure, today announced the successful completion of a 30-day preclinical study.
  • The success of this 30-day in vivo study is a significant milestone for FineHeart as we work towards first-in-human clinical trials and prove ICOMS technology as a potential game-changer in saving patients from heart failure, said Arnaud Mascarell, CEO and Founder, FineHeart.
  • Hospital readmission rates following LVAD surgery is staggering, with patients being re-admitted two to five times in the first six months following LVAD surgery.
  • Our team has developed a technology to mitigate complications and issues, such as rehospitalization.

BioVentrix Announces Pivotal ALIVE Trial Resumes with First Patients Treated with LIVE Therapy Since COVID-19 Pause

Retrieved on: 
Wednesday, September 2, 2020
Medical devices, Health, Hospitals, Clinical trials, General Health, Cardiology, Health sciences, Health, Articles, Clinical endpoint, Clinical research, Therapy, Destination therapy

COVID-19 has been reported to cause or worsen heart damage, and with the progressive nature of heart failure, delays in treatment can worsen the prognosis for patients.

Key Points: 
  • COVID-19 has been reported to cause or worsen heart damage, and with the progressive nature of heart failure, delays in treatment can worsen the prognosis for patients.
  • We are pleased that our partner centers are able to resume offering LIVE Therapy as an investigational treatment through the ALIVE Trial for these patients in need, said BioVentrix CEO Kenneth Miller.
  • The ALIVE Trial plans to enroll 120 patients at up to 25 sites in the U.S. with a primary endpoint analysis at one year.
  • View a testimonial from one patient who has experienced Less Invasive Ventricular EnhancementTM (LIVETM Therapy) using the Revivent TC System.

Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure

Retrieved on: 
Thursday, November 7, 2019
Branches of biology, Biology, Medicine, Interventional cardiology, Cardiology, Medical devices, Prosthetics, Biotechnology, Ventricular assist device, Gene therapy, Destination therapy

Our unique multigenic approach is designed to stimulate biological activity targeting multiple points in the disease progression pathway."

Key Points: 
  • Our unique multigenic approach is designed to stimulate biological activity targeting multiple points in the disease progression pathway."
  • "Heart failure is the leading cause of death worldwide and represents a significant and growing global health problem.
  • INXN-4001 is being evaluated in a Phase I open label study in adult patients with implanted Left Ventricular Assist Device (LVAD).
  • The Company's lead product is a non-viral investigational gene therapy candidate that drives expression of three candidate effector genes involved in heart failure.

Heart Pump Device (Extracorporeal and Implantable Pump) Market 2018 - Global Forecast to 2022

Retrieved on: 
Monday, May 21, 2018
Medicine, Interventional cardiology, Cardiology, Medical devices, Prosthetics, Ventricular assist device, Destination therapy, Pump, Thoratec

The "Heart Pump Device Market by Product (Ventricular Assist Device (LVAD, RVAD, BiVAD, and pVAD), Intra Aortic Balloon Pump, TAH), Type (Extracorporeal and Implantable Pump), Therapy (Bridge-to-transplant, Destination Therapy) - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Heart Pump Device Market by Product (Ventricular Assist Device (LVAD, RVAD, BiVAD, and pVAD), Intra Aortic Balloon Pump, TAH), Type (Extracorporeal and Implantable Pump), Therapy (Bridge-to-transplant, Destination Therapy) - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
  • The global heart pump devices market is projected to reach USD 3.98 Billion by 2022 from an estimated USD 1.64 Billion in 2017, at a CAGR of 19.4% during the forecast period.
  • The heart pump device market is segmented on the basis of product, type, therapy, and region.
  • Based on type, the global heart pump devices market is segmented into implantable and extracorporeal heart pump devices.

Heart Pump Device Market by Product, Type, Therapy - Global Forecast to 2022

Retrieved on: 
Thursday, May 17, 2018
Interventional cardiology, Health, Medicine, Destination therapy, Therapy, Organ transplantation

The global heart pump devices market is projected to reach USD 3.98 billion by 2022 from an estimated USD 1.64 billion in 2017, at a CAGR of 19.4% during the forecast period.

Key Points: 
  • The global heart pump devices market is projected to reach USD 3.98 billion by 2022 from an estimated USD 1.64 billion in 2017, at a CAGR of 19.4% during the forecast period.
  • Based on therapy, the global heart pump devices market is segmented into bridge-to-transplant, bridge-to-candidacy, destination therapy, and other therapies such as bridge-to-recovery and rescue therapy.
  • The report analyzes the heart pump devices market and aims at estimating the market size and future growth potential of this market based on various segments such as product, type, therapy, and region.
  • This report provides insights into the following pointers:
    Market Penetration: Comprehensive information on the product portfolios of the top players in the heart pump devices market.

Heart Pump Devices Market Worth 3.98 Billion USD by 2022

Retrieved on: 
Thursday, May 10, 2018
Medicine, Cardiology, Interventional cardiology, Medical devices, Prosthetics, Ventricular assist device, Artificial heart, Intra-aortic balloon pump, Destination therapy, Thoratec, O. H. Frazier

According to a new market research report "Heart Pump Device Market by Product (Ventricular Assist Device (LVAD, RVAD, BiVAD, and pVAD), Intra Aortic Balloon Pump, TAH), Type (Extracorporeal and Implantable Pump), Therapy (Bridge-to-transplant, Destination Therapy) - Global Forecast to 2022", published by MarketsandMarkets, the global market is projected to reach USD 3.98 Billion by 2022 from an estimated USD 1.64 Billion in 2017, at a CAGR of 19.4% during the forecast period (2017-2022).

Key Points: 
  • According to a new market research report "Heart Pump Device Market by Product (Ventricular Assist Device (LVAD, RVAD, BiVAD, and pVAD), Intra Aortic Balloon Pump, TAH), Type (Extracorporeal and Implantable Pump), Therapy (Bridge-to-transplant, Destination Therapy) - Global Forecast to 2022", published by MarketsandMarkets, the global market is projected to reach USD 3.98 Billion by 2022 from an estimated USD 1.64 Billion in 2017, at a CAGR of 19.4% during the forecast period (2017-2022).
  • On the basis of product, the Heart Pump Devices Market is segmented into ventricular assist devices, intra-aortic balloon pumps, and total artificial heart.
  • On the basis of type, the Heart Pump Devices Market is segmented into implantable and extracorporeal heart pump devices.
  • In 2017, the implantable heart pump devices segment is expected to account for the largest share of the global market.